[1]
|
Danova, M., Barni, S., Del Mastro, L., Danesi, R. and Pappagallo, G.L. (2011) Optimal Use of Recombinant Granulo-cyte Colony-Stimulating Factor with Chemotherapy for Solid Tumors. Expert Review of Anticancer Therapy, 11, 1303-1313. https://doi.org/10.1586/era.11.72
|
[2]
|
李惠平, 樊征夫, 郑虹, 等. 聚乙二醇化重组人粒细胞集落刺激因子初级与次级预防化疗后中性粒细胞减少的有效性和安全性临床研究[J]. 中国肿瘤临床, 2019, 46(14): 739-744.
|
[3]
|
Denduluri, N., Patt, D.A., Wang, Y., et al. (2015) Dose Delays, Dose Reductions, and Relative Dose In-tensity in Patients with Cancer Who Received Adjuvant or Neoadjuvant Chemotherapy in Community Oncology Practic-es. Official Journal of the National Comprehensive Cancer Network, 13, 1383-1393. https://doi.org/10.6004/jnccn.2015.0166
|
[4]
|
Link, B.K., Budd, G.T., Scott, S., et al. (2001) Delivering Adjuvant Chemotherapy to Women with Early-Stage Breast Carcinoma: Current Patterns of Care. Cancer, 92, 1354-1367.
https://doi.org/10.1002/1097-0142(20010915)92:6%3C1354::AID-CNCR1458%3E3.0.CO;2-P
|
[5]
|
秦叔逵, 马军. 中国临床肿瘤学会(CSCO)肿瘤放化疗相关中性粒细胞减少症规范化管理指南(2021) [J]. 临床肿瘤学杂志, 2021, 26(7): 638-648.
|
[6]
|
Sugimoto, Y., Katayama, N., Masuya, M. and Shiku, H. (2005) Differential Requirement for Cell Division in the Development of Terminally Differentiated Neutrophils and Macrophages from Their Common Pro-genitors. Blood, 106, 2218. https://doi.org/10.1182/blood.V106.11.2218.2218
|
[7]
|
Becker, P.S., Griffiths, E.A., Alwan, L.M., Bachiashvili, K. and Pluchino, L.A. (2020) NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020. Journal of the National Comprehensive Cancer Network: JNCCN, 18, 12-22. https://doi.org/10.6004/jnccn.2020.0002
|
[8]
|
王蕾, 颜晓菁, 何娟. PEG-rhG-CSF与G-CSF预防及治疗化疗后中性粒细胞缺乏的效果比较[J]. 现代肿瘤医学, 2021, 29(7): 1215-1219.
|
[9]
|
马军, 秦叔逵, 朱军, 李进. 硫培非格司亭临床应用专家共识[J]. 临床肿瘤学杂志, 2020, 25(5): 461-465.
|
[10]
|
贺晶晶, 高俊珍. 聚乙二醇化重组人粒细胞集落刺激因子的应用进展[J]. 国际呼吸杂志, 2020, 40(16): 1255-1261.
|
[11]
|
周建红, 罗文苹, 张日光, 黄慧娴, 刘春琳. 聚乙二醇化重组人粒细胞集落刺激因子的临床应用进展[J]. 医学综述, 2021, 27(15): 3067-3072.
|
[12]
|
Xu, N., Yan, H., Mao, C., et al. (2021) 1711P Real-World Study of Mecapegfilgrastim in Preventing Neutropenia in Patients with Gastrointestinal Tumors. Annals of Oncology, 32, S1191. https://doi.org/10.1016/j.annonc.2021.08.1683
|
[13]
|
Wang, X.G., He, Y.J., Wang, T.F., et al. (2019) Efficacy of Pegfilgrastim to Support Neoadjuvant Dose-Dense Epirubicin and Cyclophosphamide Chemotherapy in Breast Cancer. Supportive Care in Cancer, 27, 3019-3025.
https://doi.org/10.1007/s00520-018-4572-8
|
[14]
|
Kuendgen, A., Fenk, R., Bruns, I., et al. (2006) Splenic Rupture Following Administration of Pegfilgrastim in a Patient with Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation. Bone Marrow Transplantation, 38, 69-70. https://doi.org/10.1038/sj.bmt.1705382
|
[15]
|
Hershman, D., Neugut, A.I., Jacobson, J.S., Hershman, D., Neugut, A.I., Jacobson, J.S., Wang, J., Tsai, W.Y., McBride, R., et al. (2007) Acute Myeloid Leukemia or Myelodysplastic Syn-drome Following Use of Granulocyte Colony-Stimulating Factors during Breast Cancer Adjuvant Chemotherapy. Jour-nal of the National Cancer Institute, 99, 196-205. https://doi.org/10.1093/jnci/djk028
|
[16]
|
Lambertini, M., Bruzzi, P., Poggio, F., et al. (2016) Pegfilgrastim Administration after 24 or 72 or 96 h to Allow Dose-Dense Anthracycline- and Taxane-Based Chemotherapy in Breast Cancer Patients: A Single-Center Experience within the GIM2 Randomized Phase III Trial. Supportive Care in Cancer, 24, 1285-1294.
https://doi.org/10.1007/s00520-015-2907-2
|
[17]
|
Liu, C., Hao, Y., Wang, L., Meng, F., Wen, F. and Zhong, D. (2021) Safety and Efficacy of Administering Reduced Doses of Pegylated Recombinant Human Granulocyte-Colony Stimulating Factors in Patients Treated with Cisplatin and Etoposide for Small Cell Carcinoma: A Retrospective Study. Thoracic Cancer, 12, 1154-1161.
https://doi.org/10.1111/1759-7714.13883
|
[18]
|
曹威, 何英剑, 欧阳涛, 等. 每周期4.5 mg聚乙二醇化重组人粒细胞集落刺激因子支持乳腺癌剂量密集型化疗疗效观察[J]. 中华肿瘤防治杂志, 2021, 28(19): 1488-1492.
|
[19]
|
Perrier, L., Lefranc, A., Pérol, D., et al. (2013) Cost Effectiveness of Pegfilgrastim versus Filgrastim after High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients with Lymphoma and Myeloma: An Economic Evaluation of the PALM Trial. Applied Health Economics and Health Policy, 11, 129-138.
https://doi.org/10.1007/s40258-013-0011-7
|
[20]
|
Ramsey, S.D., Liu, Z., Boer, R., et al. (2009) Cost-Effectiveness of Primary versus Secondary Prophylaxis with Pegfilgrastim in Women with Early-Stage Breast Cancer Receiving Chemotherapy. Value Health, 12, 217-225.
https://doi.org/10.1111/j.1524-4733.2008.00434.x
|
[21]
|
夏雯, 王树森, 胡皓, 等. 中国早期乳腺癌患者化疗后接受聚乙二醇化重组人粒细胞刺激因子初级预防的成本效果分析[J]. 中华肿瘤杂志, 2020, 42(10): 861-867.
|
[22]
|
Wu, Q., Li, Q., Zhang, J., et al. (2021) Comparison of Primary and Secondary Prophylaxis Using PEGylated Recombinant Human Granulocyte-Stimulating Factor as a Cost-Effective Measure in Malignant Neoplasms: A Multicenter Retrospective Study. Frontiers in Pharmacology, 12, Article ID: 690874. https://doi.org/10.3389/fphar.2021.690874
|
[23]
|
Zhao, J., Qiao, G., Liang, Y., et al. (2021) Cost-Effectiveness Analysis of PEG-rhG-CSF as Primary Prophylaxis to Chemotherapy-Induced Neutropenia in Women with Breast Can-cer in China: Results Based on Real-World Data. Frontiers in Pharmacology, 12, Article ID: 754366. https://doi.org/10.3389/fphar.2021.754366
|
[24]
|
Smith, T.J., Khatcheressian, J., Lyman, G.H., et al. (2006) 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline. Journal of Clinical Oncology, 24, 3187-3205. https://doi.org/10.1200/JCO.2006.06.4451
|
[25]
|
Kam, G., Yiu, R., Loh, Y., et al. (2015) Impact of Pegylated Filgrastim in Comparison to Filgrastim for Patients with Acute Mye-loid Leukaemia (AML) on High-Dose Cytarabine (HIDAC) Consolidation Chemotherapy. Support Care Cancer, 23, 643-649. https://doi.org/10.1007/s00520-014-2417-7
|
[26]
|
Sperr, W.R., Herndlhofer, S., Gleixner, K., et al. (2017) Intensive Consolidation with G-CSF Support: Tolerability, Safety, Reduced Hospitalization, and Efficacy in Acute Mye-loid Leukemia Patients ≥60 Years. American Journal of Hematology, 92, E567-E574. https://doi.org/10.1002/ajh.24847
|
[27]
|
刘凯奇, 王迎, 赵姿, 等. 初诊急性髓系白血病诱导治疗后聚乙二醇化重组人G-CSF与普通重组人G-CSF促进中性粒细胞恢复的单中心随机对照研究[J]. 中华血液学杂志, 2019, 40(6): 497-501.
|
[28]
|
杨文钰, 刘天峰, 陈晓娟, 等. 聚乙二醇化重组人粒细胞集落刺激因子在儿童急性淋巴细胞白血病的药代动力学和药效学的前瞻性对照研究[J]. 中国当代儿科杂志, 2020, 22(11): 1172-1177.
|
[29]
|
Liu, X.T., Zhao, Y.X., Jia, G.W., et al. (2021) Pharmacokinetics and Safety of Pegylated Recombinant Human Granulocyte Colo-ny-Stimulating Factor in Children with Acute Leukaemia. British Journal of Clinical Pharmacology, 87, 3292-3300. https://doi.org/10.1111/bcp.14750
|
[30]
|
Paolo, A. and Champlin, R.E. (2008) Biologic and Molecular Effects of Granulocyte Colony-Stimulating Factor in Healthy Individuals: Recent Findings and Current Challenges. Blood, 111, 1767-1772.
https://doi.org/10.1182/blood-2007-07-097543
|
[31]
|
Franzke, A., Piao, W., Lauber, J., et al. (2003) G-CSF as Immune Regulator in T Cells Expressing the G-CSF Receptor: Implications for Transplantation and Autoimmune Dis-eases. Blood, 102, 734-739.
https://doi.org/10.1182/blood-2002-04-1200
|
[32]
|
Anderlini, P. (2009) Effects and Safety of Granulocyte Colo-ny-Stimulating Factor in Healthy Volunteers. Current Opinion in Hematology, 16, 35-40. https://doi.org/10.1097/MOH.0b013e328319913c
|
[33]
|
Cornet, S., Mathé, D., Chettab, K., et al. (2016) Pegfil-grastim Enhances the Antitumor Effect of Therapeutic Monoclonal Antibodies. Molecular Cancer Therapeutics, 15, 1238-1247. https://doi.org/10.1158/1535-7163.MCT-15-0759
|
[34]
|
Gruber, M., Fleiss, K., Porpaczy, E., et al. (2011) Prolonged Progression-Free Survival in Patients with Chronic Lymphocytic Leukemia Receiving Granulocyte Colony-Stimulating Factor during Treatment with Fludarabine, Cyclophosphamide, and Rituximab. Annals of Hematolo-gy, 90, 1131-1136. https://doi.org/10.1007/s00277-011-1260-x
|
[35]
|
Huang, W., Liu, J., Zeng, Y., et al. (2018) Randomized Controlled Clinical Trial of Polyethylene Glycol Recombinant Human Granulocyte Colony-Stimulating Factor in the Treatment of Neutropenia after Chemotherapy for Breast Cancer. Cancer Chemotherapy and Pharmacology, 82, 607-613. https://doi.org/10.1007/s00280-018-3639-z
|
[36]
|
Zlotnik, A. and Yoshie, O. (2000) Chemokines: A New Classification System and Their Role in Immunity. Immunity, 12, 121-127. https://doi.org/10.1016/S1074-7613(00)80165-X
|
[37]
|
Sun, J., Bai, H., Wang, Z., et al. (2020) Pegylated Recom-binant Human Granulocyte Colony-Stimulating Factor Regulates the Immune Status of Patients with Small Cell Lung Cancer. Thoracic Cancer, 11, 713-722.
https://doi.org/10.1111/1759-7714.13322
|
[38]
|
Rutella, S., Danese, S. and Leone, G. (2006) Tolerogenic Dendritic Cells: Cytokine Modulation Comes of Age. Blood, 108, 1435-1440. https://doi.org/10.1182/blood-2006-03-006403
|
[39]
|
Tanaka, J., Mielcarek, M. and Torok-Storb, B. (1998) Im-paired Induction of the CD28-Responsive Complex in Granulocyte Colony-Stimulating Factor Mobilized CD4 T Cells. Blood, 91, 347-352.
https://doi.org/10.1182/blood.V91.1.347
|
[40]
|
Morris, E.S., MacDonald, K.P., Rowe, V., et al. (2004) Donor Treatment with Pegylated G-CSF Augments the Generation of IL-10-Producing Regulatory T Cells and Promotes Trans-plantation Tolerance. Blood, 103, 3573-3581.
https://doi.org/10.1182/blood-2003-08-2864
|
[41]
|
Bonanno, G., Procoli, A., Mariotti, A., et al. (2010) Effects of Pegylated G-CSF on Immune Cell Number and Function in Patients with Gynecological Malignancies. Journal of Translational Medicine, 8, 114.
https://doi.org/10.1186/1479-5876-8-114
|
[42]
|
Studnicka, M., Wirnsberger, R., Neumann, M., Pokieser, L. and Angerler, J. (1994) Peripheral Blood Lymphocyte Subsets and Survival in Small-Cell Lung Cancer. Chest, 105, 1673-1678. https://doi.org/10.1378/chest.105.6.1673
|
[43]
|
Huang, C.T., Wen, Y.T., Desai, T.D. and Tsai, R.K. (2021) Intravitreal Injection of Long-Acting Pegylated Granulocyte Colony-Stimulating Factor Provides Neuroprotective Effects via Antioxidant Response in a Rat Model of Traumatic Optic Neuropathy. Antioxidants, 10, Article No. 1934. https://doi.org/10.3390/antiox10121934
|
[44]
|
Ji, X., Xu, L.S., Pan, P.F., Xu, Z.Y., Wang, A.H. and Li, Y. (2021) Efficacy and Safety of 3 mg Pegylated Recombinant Human Granulocyte Colony-Stimulating Factor as Support to Chemotherapy for Lung Cancer. Thoracic Cancer, 13, 117-125. https://doi.org/10.1111/1759-7714.14233
|
[45]
|
Haller, M.J., Atkinson, M.A., Wasserfall, C.H., et al. (2016) Mobi-lization without Immune Depletion Fails to Restore Immunological Tolerance or Preserve Beta Cell Function in Recent Onset Type 1 Diabetes. Clinical & Experimental Immunology, 183, 350-357. https://doi.org/10.1111/cei.12731
|